Critical Molecular Pathways in Cancer Stem Cells of Chronic Myeloid Leukemia

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2010 Jun 25

PMID 20574455

Citations 28

Authors

Y Chen

C Peng

C Sullivan

D Li

S Li

Affiliations

Soon will be listed here.

Abstract

Inhibition of BCR-ABL with kinase inhibitors in the treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) is highly effective in controlling but not curing the disease. This is largely due to the inability of these kinase inhibitors to kill leukemia stem cells (LSCs) responsible for disease relapse. This stem cell resistance is not associated with the BCR-ABL kinase domain mutations resistant to kinase inhibitors. Development of curative therapies for CML requires the identification of crucial molecular pathways responsible for the survival and self-renewal of LSCs. In this review, we will discuss our current understanding of these crucial molecular pathways in LSCs and the available therapeutic strategies for targeting these stem cells in CML.

Citing Articles

BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP.

Feng L, Ding R, Qu X, Li Y, Shen T, Wang L Cell Death Dis. 2023; 14(4):287.

PMID: 37095099 PMC: 10125982. DOI: 10.1038/s41419-023-05811-2.

A Dual Level Analysis with Evolutionary Computing and Swarm Models for Classification of Leukemia.

Prabhakar S, Ryu S, Jeong I, Won D Biomed Res Int. 2022; 2022:2052061.

PMID: 35663047 PMC: 9162867. DOI: 10.1155/2022/2052061.

Sphingosine kinases are involved in the regulation of all-trans retinoic acid sensitivity of K562 chronic myeloid leukemia cells.

Sun D, Wang S Oncol Lett. 2021; 22(2):581.

PMID: 34122632 PMC: 8190775. DOI: 10.3892/ol.2021.12842.

Hedgehog Signaling and Truncated GLI1 in Cancer.

Doheny D, Manore S, Wong G, Lo H Cells. 2020; 9(9).

PMID: 32957513 PMC: 7565963. DOI: 10.3390/cells9092114.

Signaling pathways involved in chronic myeloid leukemia pathogenesis: The importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells.

Moradi F, Babashah S, Sadeghizadeh M, Jalili A, Hajifathali A, Roshandel H Iran J Basic Med Sci. 2019; 22(6):581-589.

PMID: 31231484 PMC: 6570743. DOI: 10.22038/ijbms.2019.31879.7666.

References

Anderson K, Seed T, Plate J, Jajeh A, Meng J, Harris J . Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Leuk Res. 1995; 19(11):789-801. DOI: 10.1016/0145-2126(95)00043-7. View

Chang D, Lopez A, von Kessler D, Chiang C, Simandl B, Zhao R . Products, genetic linkage and limb patterning activity of a murine hedgehog gene. Development. 1994; 120(11):3339-53. DOI: 10.1242/dev.120.11.3339. View

Koschmieder S, Gottgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok J . Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2004; 105(1):324-34. DOI: 10.1182/blood-2003-12-4369. View

Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-80. DOI: 10.1126/science.1062538. View

Minami Y, Stuart S, Ikawa T, Jiang Y, Banno A, Hunton I . BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A. 2008; 105(46):17967-72. PMC: 2582213. DOI: 10.1073/pnas.0808303105. View

Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y . TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010; 463(7281):676-80. DOI: 10.1038/nature08734. View

Covey T, Edes K, Fitzpatrick F . Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene. 2007; 26(39):5784-92. DOI: 10.1038/sj.onc.1210391. View

Zhao L, Moos M, Grabner R, Pedrono F, Fan J, Kaiser B . The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med. 2004; 10(9):966-73. DOI: 10.1038/nm1099. View

Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S . Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004; 10(10):3371-6. DOI: 10.1158/1078-0432.CCR-03-0508. View

10.

Pear W, Miller J, Xu L, Pui J, Soffer B, Quackenbush R . Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998; 92(10):3780-92. View

11.

Kelliher M, McLaughlin J, Witte O, Rosenberg N . Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990; 87(17):6649-53. PMC: 54594. DOI: 10.1073/pnas.87.17.6649. View

12.

Kops G, Medema R, Glassford J, Essers M, Dijkers P, Coffer P . Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol. 2002; 22(7):2025-36. PMC: 133681. DOI: 10.1128/MCB.22.7.2025-2036.2002. View

13.

Bhatia R, Holtz M, Niu N, Gray R, Snyder D, Sawyers C . Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003; 101(12):4701-7. DOI: 10.1182/blood-2002-09-2780. View

14.

Peters-Golden M, Henderson Jr W . Leukotrienes. N Engl J Med. 2007; 357(18):1841-54. DOI: 10.1056/NEJMra071371. View

15.

Jordan C, Guzman M, Noble M . Cancer stem cells. N Engl J Med. 2006; 355(12):1253-61. DOI: 10.1056/NEJMra061808. View

16.

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

17.

Dierks C, Beigi R, Guo G, Zirlik K, Stegert M, Manley P . Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell. 2008; 14(3):238-49. DOI: 10.1016/j.ccr.2008.08.003. View

18.

Copland M, Hamilton A, Elrick L, Baird J, Allan E, Jordanides N . Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107(11):4532-9. DOI: 10.1182/blood-2005-07-2947. View

19.

Mughal T, Yong A, Szydlo R, Dazzi F, Olavarria E, van Rhee F . Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol. 2001; 115(3):569-74. DOI: 10.1046/j.1365-2141.2001.03155.x. View

20.

Bruns I, Czibere A, Fischer J, Roels F, Cadeddu R, Buest S . The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia. 2009; 23(5):892-9. DOI: 10.1038/leu.2008.392. View